Brief: Ngm Bio Presents Early Findings From Ongoing Phase 1A/1B Study Of Ngm120 In Advanced Solid Tumors At ESMO 2021
16/09/2021 13:39
Sept 16 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO PRESENTS PRELIMINARY FINDINGS FROM ONGOING PHASE
1A/1B
DOSE ESCALATION STUDY OF NGM120 IN PATIENTS WITH ADVANCED SOLID
TUMORS AT ESMO VIRTUAL CONGRESS 2021
* NGM BIOPHARMACEUTICALS INC - NGM120 HAS BEEN WELL
TOLERATED TO
DATE IN PATIENTS IN PHASE 1A/1B STUDY WITH NO DOSE-LIMITING
TOXICITIES
* NGM - ALL SIX EVALUABLE METASTATIC PANCREATIC CANCER
PATIENTS IN
PHASE 1B COMBINATION COHORT DEMONSTRATED DISEASE CONTROL AT 16
WEEKS
* NGM - FOUR METASTATIC PANCREATIC CANCER PATIENTS IN PHASE
1B
COHORT CONTINUED TO EXHIBIT PR/SD BEYOND 36 WEEKS AT JULY 26(TH)
DATA CUT-OFF
Source text for Eikon: ID:nGNXc6lprk
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors